After Hours Summary: MRVL +17.8%, GPS +14.4%, WDAY +7.9% higher on earnings; ULTA -7.3%, DECK -2.7%, RH -2.2%, COST -0.2% lower on earningsAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: MRVL +17.8%, GPS +14.4%, WDAY +7.9% (also names new CFO), ARCE +3.1%, ME +2.9%, LGF.A +2.5%, DOMO +1.8%
Companies trading higher in after hours in reaction to news: PDSB +13.1% (announces interim data on PDS0101), GNLX +6.4% (announces publication of topline data from Phase 2 VIRO-15 Trial), CUE +6.3% (presents data from phase 1 trials of CUE-101), PARA +5.7% (controlling shareholder secures $125 mln investment), CGEM +5.6% (to present first monotherapy clinical data for CLN-619), TALO +3.5% (Zamajal to acquire a 49.9% interest in Talos's Mexican subsidiary), GPCR +2% (initiates Phase 2a study of GSBR-1290), BOH +2% (to move to S&P SmallCap 600 from S&P MidCap 400), THRX +1.9% (reports data from ongoing Phase 1/2 trial of THE-630), GERN +0.6% (NDA submission on track for June 2023), REGN +0.3% (announces data evaluating combo of fianlimab and Libtayo), TEVA +0.3% (exploring options for bowel inflammation drug, including a potential sale, according to Bloomberg), F +0.3% (reaches agreement with TSLA providing Ford EV customers access to Tesla Superchargers), WTM +0.2% (names new chairman), VMW +0.1% (names new CFO)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: ULTA -7.3%, DECK -2.7%, RH -2.2%, ADSK -0.4%, COST -0.2%
Companies trading lower in after hours in reaction to news: TLRY -19.1% (commences $150 convertible notes offering), HMST -4.2% (to be removed from S&P Small Cap 600), RLAY -1.9% (announces full dose escalation data for RLY-4008), EXAS -1.3% (files mixed shelf securities offering), HLI -1.2% (reports certain revised financial info), MDU -0.4% (KNF to join S&P MidCap 400 after spin-off), IMAB -0.3% (announces phase 1b/2 study results of patients with advanced NSCLC), MRK -0.2% (announces data from pivotal Phase 3 CLEAR study 307), PFE -0.1% (presents scientific advancements from its leading oncology portfolio), BMY -0.1% (announces results from pivotal TRANSCEND CLL 004 study)